Search Result

Results for "

STAT3-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (4) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (2) Annexin A (1) Apoptosis (11) Bacterial (1) Bcl-2 Family (3) c-Met/HGFR (1) c-Myc (1) Carbonic Anhydrase (1) Caspase (2) Discoidin Domain Receptor (1) EGFR (1) Endogenous Metabolite (4) ERK (1) Exosomes (1) Ferroptosis (1) Hedgehog (1) Interleukin Related (7) Isotope-Labeled Compounds (3) JAK (7) Microtubule/Tubulin (1) Mitosis (1) mTOR (2) Na+/K+ ATPase (1) nAChR (2) NF-κB (1) NO Synthase (2) PI3K (1) Polo-like Kinase (PLK) (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Src (1) STAT (27) TAM Receptor (1) TET Protein (1) TGF-β Receptor (1) VEGFR (2)
By Research Areas:	Cancer (31) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (10) Metabolic Disease (4) Neurological Disease (3)

By Targets:

Akt (4)

Amyloid-β (1)

Anaplastic lymphoma kinase (ALK) (2)

Annexin A (1)

Apoptosis (11)

Bacterial (1)

Bcl-2 Family (3)

c-Met/HGFR (1)

c-Myc (1)

Carbonic Anhydrase (1)

Caspase (2)

Discoidin Domain Receptor (1)

EGFR (1)

Endogenous Metabolite (4)

ERK (1)

Exosomes (1)

Ferroptosis (1)

Hedgehog (1)

Interleukin Related (7)

Isotope-Labeled Compounds (3)

JAK (7)

Microtubule/Tubulin (1)

Mitosis (1)

mTOR (2)

Na+/K+ ATPase (1)

nAChR (2)

NF-κB (1)

NO Synthase (2)

PI3K (1)

Polo-like Kinase (PLK) (1)

Ras (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

Src (1)

STAT (27)

TAM Receptor (1)

TET Protein (1)

TGF-β Receptor (1)

VEGFR (2)

By Research Areas:

Cancer (31)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (10)

Metabolic Disease (4)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113261

Oleoylcarnitine	Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via *STAT3* activation .

HY-100753

*STAT3-IN-1* Maximum Cited Publications 11 Publications Verification	STAT Apoptosis	Cancer
STAT3-IN-1 (compound 7d) is an excellent, selective and orally active *STAT3* inhibitor, with IC₅₀ values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis .

HY-122258

NSC-370284	STAT TET Protein	Cancer
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets *STAT3/5* .

HY-B0667

Balsalazide	Interleukin Related STAT	Inflammation/Immunology Cancer
Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the *IL-6/STAT3* pathway .

HY-146066

α7 nAchR-JAK2-STAT3 agonist 1	nAChR JAK STAT NO Synthase Interleukin Related	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-121418

Lusianthridin	c-Myc	Cancer
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling .

HY-112391

SD-1029 1 Publications Verification	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation .

HY-B0667A

Balsalazide sodium hydrate Balsalazide disodium dihydrate	Interleukin Related STAT	Inflammation/Immunology Cancer
Balsalazide sodium hydrate is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the *IL-6/STAT3* pathway .

HY-N1280

Semilicoisoflavone B	Amyloid-β	Neurological Disease
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces amyloid β (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation .

HY-N0885

Telocinobufagin 1 Publications Verification TelobufotoxIN; TelocINobufogenIN	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the *STAT3, JAK2/STAT3, LARP1-mTOR*, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-N10336

Notoginsenoside R4	VEGFR STAT Akt Ras	Others
Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3 .

HY-161015

JAK1-IN-13	JAK	Inflammation/Immunology
JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of JAK1 with an IC₅₀ of 0.044 nM. JAK1-IN-13 significantly decreases *STAT3* phosphorylation .

HY-125355

SEC 1 Publications Verification	Apoptosis Annexin A	Cancer
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation .

HY-P10641

Heart-homing peptide	Exosomes STAT ERK Akt	Cardiovascular Disease
Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the *GP130-STAT3/ERK1/2/AKT* pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases .

HY-P10113

STAT3-IN-23	STAT	Cancer
STAT3-IN-23 (PYLKTK) is a potent STAT3* inhibitor .

HY-100753R

STAT3-IN-1 (Standard)	STAT Reference Standards Apoptosis	Cancer
STAT3-IN-1 (Standard) is the analytical standard of STAT3-IN-1 (HY-100753). This product is intended for research and analytical applications. STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis .

HY-147048

*STAT3 degrader-1*	STAT	Cancer
STAT3 degrader-1 (compound 295) is a potent *STAT3* degrader. STAT3 degrader-1 can be used for researching anticancer . STAT3 degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N3913

Furowanin A	STAT Bcl-2 Family	Cancer
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits *STAT3/Mcl-1* axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .

HY-146066A

(R)-α7 nAchR-JAK2-STAT3 agonist 1	nAChR JAK STAT NO Synthase	Others
(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-113261S

Oleoylcarnitine-d9	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine-d₉ is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via *STAT3* activation .

HY-161136

EGFR/STAT3-IN-1	EGFR STAT	Cancer
EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC₅₀ values for EGFR and *STAT3* are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .

HY-174457

STAT3/CAIX-IN-1	STAT Carbonic Anhydrase Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Caspase Bcl-2 Family	Cancer
STAT3/CAIX-IN-1 is a dual-target inhibitor of *STAT3* (K_d: 60.03 μM) and CAIX (IC₅₀: 80.45 nM). STAT3/CAIX-IN-1 induces ferroptosis by increases the levels of reactive oxygen species (ROS) and lipid peroxides. STAT3/CAIX-IN-1 inhibits cell migration, induces apoptosis, and causes cell cycle arrest in MDA-MB-231 cells. STAT3/CAIX-IN-1 can be used for the study of triple-negative breast cancer (TNBC) .

HY-175227

STAT3/NF-κB-IN-1	STAT NF-κB Apoptosis Caspase Bcl-2 Family	Cancer
STAT3/NF-κB-IN-1 is a potentSTAT3 and NF-κB inhibitor with IC₅₀s of 5.86 (STAT3) and 4.22 μM (NF-κB) in 4T1 cells. STAT3/NF-κB-IN-1 is able to induce apoptosis via its upregulation on key apoptotic regulators; caspases-3/9, Bax and downregulation of Bcl-2. STAT3/NF-κB-IN-1 exerts considerable anticancer activity against breast cancer cell lines and reduces tumor volume in vivo. STAT3/NF-κB-IN-1 can be used for the study of breast cancer .

HY-175298

STAT-3/c-Src-IN-1	STAT Src Apoptosis	Cancer
STAT-3/c-Src-IN-1 (Compound 12d) is a dual *STAT-3* (IC₅₀=0.844 μM) and c-Src (IC₅₀=0.268 μM) inhibitor. STAT-3/c-Src-IN-1 blocks tumor cell proliferation, migration, and angiogenesis signaling pathways. STAT-3/c-Src-IN-1 exhibits potent anti-proliferative activity against melanoma (SK-MEL-2) and CNS cancer (SNB-75) cell lines (GI₅₀=-5.75 μM and -5.63 μM), inducing tumor cell apoptosis via G0/G1 and G2/M phase cell cycle arrest. STAT-3/c-Src-IN-1 is promising for research of melanoma and glioblastoma .

HY-131194

JAK2/STAT3-IN-1	Interleukin Related	Cancer
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

HY-161859

VEGFR-2/STAT-3-IN-1	VEGFR STAT	Cancer
VEGFR-2/STAT-3-IN-1 (Compound 9f) is a dual inhibitor for VEGFR-2 (IC₅₀=26.3 nM) and *STAT-3* (IC₅₀=5.63 nM). VEGFR-2/STAT-3-IN-1 inhibits the proliferation of cancer cells PANC1 and PC3 with IC₅₀ of 0.14 and 0.10 µM. VEGFR-2/STAT-3-IN-1 induces apoptosis in PC3 .

HY-167839

(R)-JAK2/STAT3-IN-1	Apoptosis	Cancer
(R)-JAK2/STAT3-IN-1 is a GP130 D1 domain inhibitor with anti-tumor activity. (R)-JAK2/STAT3-IN-1 can inhibit the phosphorylation of JAK2 and STAT3. The affinity of (R)-JAK2/STAT3-IN-1 for GP130 protein is 3.8 μM. (R)-JAK2/STAT3-IN-1 effectively inhibits the viability and migration of tumor cells and promotes apoptosis .

HY-170977

JAK1/STAT3-IN-1	JAK STAT	Inflammation/Immunology
JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting *JAK1/STAT3* signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC₅₀ of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on Calcipotriol (HY-10001) (MC903)-induced AD-like mice .

HY-156958

S-72	Apoptosis STAT Microtubule/Tubulin Mitosis	Inflammation/Immunology
S-72 inhibits tubulin polymerization and further triggers mitosis-phase cell cycle arrest and cell apoptosis, in addition to suppressing *STAT3* signaling .

HY-113261R

Oleoylcarnitine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine (Standard) is the analytical standard of Oleoylcarnitine. This product is intended for research and analytical applications. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation .

HY-108244

Balsalazide disodium	Interleukin Related STAT	Inflammation/Immunology Cancer
Balsalazide disodium is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the *IL-6/STAT3* pathway .

HY-161351

STAT3/AKT-IN-1	Akt STAT Apoptosis	Cancer
STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .

HY-B0667S

Balsalazide-d3	Isotope-Labeled Compounds Interleukin Related STAT	Cancer
Balsalazide-d₃ is the deuterium labeled Balsalazide (HY-B0667). Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway .

HY-183306

mTOR/STAT3-IN-1	mTOR STAT	Neurological Disease Inflammation/Immunology Cancer
mTOR/STAT3-IN-1 is a dual *mTOR/STAT3* inhibitor. mTOR/STAT3-IN-1 exhibits potent mTOR inhibitory activity and moderate STAT3 inhibitory activity, while exerting cell type-dependent antiproliferative and senolytic activities in human cell lines. mTOR/STAT3-IN-1 can be used in the research of glioblastoma and aging-related diseases .

HY-E70760

NPM1 ALK Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK protein that can be used to study NPM1 ALK-related functions .

HY-162803

c-Met-IN-24	Apoptosis c-Met/HGFR STAT	Cancer
c-Met-IN-24 (compound 3g) is a dual-target inhibitor of *STAT-3* ( =4.7 μM) and c-MET ( =12.67 μM) with anticancer activity. c-Met-IN-24 arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells. c-Met-IN-24 can be used in the study of central nervous system cancers .

HY-E70761

NPM1 ALK F1174L Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK F1174L protein that can be used to study NPM1 ALK F1174L-related functions .

HY-113261S1

Oleoylcarnitine-13C,d3	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Cancer
Oleoylcarnitine- ¹³C,d₃ is the deuterium and ¹³C-labeled Oleoylcarnitine (HY-113261). Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via *STAT3* activation .

HY-181872

JAK1-IN-20	JAK Interleukin Related STAT	Inflammation/Immunology
JAK1-IN-20 (Compound 38) is a gut-restricted, orally active, selective JAK1 inhibitor with an IC₅₀ of <0.5 nM. JAK1-IN-20 inhibits the enzymatic activity of JAK1, reduces the production of proinflammatory cytokines (TNF-α, IL-6), and suppresses the phosphorylation of *STAT3*. JAK1-IN-20 ameliorates ulcerative colitis. JAK1-IN-20 can be used for the research of inflammatory bowel disease .

HY-179535

Axl-IN-21	TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog	Cancer
Axl-IN-21 is an orally active and selective AXL inhibitor (K_d = 2.7 nM, IC₅₀ = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with K_d = 1.4 nM, DDR1 with IC₅₀ = 22.2 nM, HIPK4 with K_d = 11.0 nM and LOK with K_d =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced *AXL/STAT3/ABCG1* signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer ^[1] ^[2].

Cat. No.	Product Name

HY-L249

Lactylation Compound Library	5,946 compounds
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 5,946 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Lactylation Compound Library

5,946 compounds

Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.

MCE has assembled a collection of 5,946 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Cat. No.	Product Name	Target	Research Area